The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer

Purpose: Hepatocyte growth factor (HGF) stimulates tumor cell-cell interactions, matrix adhesion, migration, invasion, and angiogenesis. This factor is produced as an inactive precursor called pro-HGF, which requires proteolytic conversion, by HGF activator (HGFA) and matriptase, to evoke a biological response. Two new HGFA inhibitors, HAI-1 and HAI-2, inhibit the generation of biologically active HGF, through their interaction with HGFA. This study determined the expression of this HGF regulatory system in breast cancer. We examined HGF, the HGF receptor (c-Met), HGFA, matriptase, and the activation inhibitors (HAI-1 and HAI-2), tissues from patients with breast cancer. Experimental Design: Breast cancer tissue (n = 100) and normal background tissue (n = 20) was obtained immediately after surgery. The median follow-up for the patients was 72 months. HGF, c-Met, HGFA, matriptase-1, HAI-1, and HAI-2 expression was quantified using real-time quantitative PCR. The distribution of these factors in mammary tissues was also examined through immunohistochemistry. Results: The breast cancer specimens expressed a significantly higher level of HGF, c-Met, HGFA, HAI-1, and HAI-2, but not matriptase, compared with the normal background tissues. Tumor tissues from node-positive patients expressed a higher level of HGFA than from the patients without nodal involvement. Interestingly, HAI-2 was expressed to a lower degree in positive nodes than that of the node-negative breast cancer tissues. HAI-1 and HAI-2 were both significantly reduced in grade 3 tumors compared with the well-differentiated tumors. In addition, on comparison of Tumor-Node-Metastasis (TNM) classification groups, HAI-2 was also found to be statistically lower in the TNM 3 breast cancer group when compared with TNM groups 1 and 2, thus associated with a poor prognosis. Conclusions: This study shows that there are aberrant levels of HGF, c-Met, HGFA, HAI-1, and HAI-2 expressed in breast cancer tissues compared with background breast tissue. HAI-1 and HAI-2 are expressed to a significantly lower level in poorly differentiated breast tumors, and HAI-2 is also inversely correlated with nodal involvement and tumor spread. Overall a low level of HAI-2 in the breast cancer tissues was associated with an overall poor outlook. Therefore, the HGF regulatory system may have an important role in the progression of breast cancer.

[1]  H. Kleinman,et al.  Scatter factor induces blood vessel formation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Itoh,et al.  Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration , 2002, Pathology international.

[3]  K. Miyazawa,et al.  Proteolytic activation of hepatocyte growth factor in response to tissue injury. , 1994, The Journal of biological chemistry.

[4]  K. Miyazawa,et al.  Functional Characterization of Kunitz Domains in Hepatocyte Growth Factor Activator Inhibitor Type 1* , 2002, The Journal of Biological Chemistry.

[5]  D. Berger.  Plasmin/Plasminogen System in Colorectal Cancer , 2002, World Journal of Surgery.

[6]  A. Joseph,et al.  Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. , 1996, The American journal of pathology.

[7]  N. Kitamura,et al.  Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[8]  G. Wogan,et al.  The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Miyazawa,et al.  Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. , 1993, The Journal of biological chemistry.

[10]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[11]  N. Kitamura,et al.  Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. , 2000, Cancer research.

[12]  中村 孝夫.  Induction of Hepatocyte Growth Factor in Fibroblasts by Tumor-derived Factors Affects Invasive Growth of Tumor Cells : In Vitro Analysis of Tumor-Stromal Interactions , 1998 .

[13]  N. Funata,et al.  Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Murata,et al.  Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. , 1999, Cancer letters.

[15]  S. Hirono,et al.  Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. , 2001, Biochemical and biophysical research communications.

[16]  K. Matsumoto,et al.  Purification and Cloning of Hepatocyte Growth Factor Activator Inhibitor Type 2, a Kunitz-type Serine Protease Inhibitor* , 1997, The Journal of Biological Chemistry.

[17]  K. Matsumoto,et al.  Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. , 1998, British Journal of Cancer.

[18]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.

[19]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[20]  I. Bièche,et al.  Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.

[21]  K. Miyazawa,et al.  Hepatocyte Growth Factor Activator Inhibitor Type 1 Is a Specific Cell Surface Binding Protein of Hepatocyte Growth Factor Activator (HGFA) and Regulates HGFA Activity in the Pericellular Microenvironment* , 2000, The Journal of Biological Chemistry.

[22]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[23]  H. Allgayer,et al.  Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Foekens,et al.  Expression of urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in benign, borderline, malignant primary and metastatic ovarian tumors , 1996, International journal of cancer.

[25]  H. Friess,et al.  Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. , 1998, Biochimica et biophysica acta.

[26]  R. Mansel,et al.  Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes , 2003, International journal of cancer.

[27]  R. Kramer,et al.  Expression of the C‐Met/HGF receptor in human breast carcinoma: Correlation with tumor progression , 1997, International journal of cancer.

[28]  B. Elliott,et al.  The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. , 2002, Canadian journal of physiology and pharmacology.

[29]  K. Martin,et al.  Identifying expressed genes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Stoppacciaro,et al.  Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis , 2001, The Journal of pathology.

[31]  K. Matsumoto,et al.  Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. , 1999, Journal of biochemistry.

[32]  K. Nabeshima,et al.  Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas. , 2000, Cancer letters.

[33]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[34]  T. Imazawa,et al.  Serum concentrations of hepatocyte growth factor in breast cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[36]  R. Dickson,et al.  Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine Protease* , 2000, The Journal of Biological Chemistry.

[37]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[38]  W. Jiang,et al.  Quantitative analysis of lymphangiogenic markers in human colorectal cancer. , 2003, International journal of oncology.

[39]  M. Takigawa,et al.  Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. , 2002, European journal of biochemistry.

[40]  P Zola,et al.  Overexpression of the MET/HGF receptor in ovarian cancer , 1994, International journal of cancer.

[41]  R. Poulsom,et al.  Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. , 1995, Cancer research.

[42]  Baljit Singh,et al.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. , 2003, Cancer research.

[43]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[44]  W. Jiang,et al.  Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. , 2001, International journal of oncology.

[45]  J. Sugawara,et al.  Hepatocyte Growth Factor Stimulates Proliferation, Migration, and Lumen Formation of Human Endometrial Epithelial Cells In Vitro , 1997 .

[46]  R. Dickson,et al.  Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. , 2001, The American journal of pathology.

[47]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.

[48]  H. Allgayer,et al.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns , 2004, Clinical & Experimental Metastasis.

[49]  R. Kannagi,et al.  [Hepatocyte growth factor in the sera of patients with gastrointestinal and breast cancer]. , 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

[50]  M. Toi,et al.  Increase in the circulating level of hepatocyte growth-factor in breast-cancer patients with distant metastases. , 1994, Oncology reports.

[51]  K. Miyazawa,et al.  Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor* , 1997, The Journal of Biological Chemistry.

[52]  S. Varnum,et al.  Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. , 2002, Journal of proteome research.